Moore Capital Management LP Purchases New Shares in BioCryst Pharmaceuticals, Inc. $BCRX

Moore Capital Management LP purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 848,336 shares of the biotechnology company’s stock, valued at approximately $8,483,000.

Other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after buying an additional 1,458 shares during the last quarter. Cetera Investment Advisers increased its holdings in shares of BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 1,494 shares during the period. Captrust Financial Advisors raised its stake in shares of BioCryst Pharmaceuticals by 7.4% during the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 1,527 shares during the last quarter. Legato Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 10.0% during the fourth quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 2,172 shares during the period. Finally, Creative Planning lifted its holdings in shares of BioCryst Pharmaceuticals by 2.6% during the third quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock worth $672,000 after purchasing an additional 2,280 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BCRX has been the topic of a number of analyst reports. Cantor Fitzgerald boosted their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. JPMorgan Chase & Co. assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They set a “neutral” rating and a $12.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Finally, Royal Bank Of Canada lowered their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $9.82 on Monday. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22. The stock’s fifty day moving average is $9.71 and its two-hundred day moving average is $9.07.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.15 EPS. As a group, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.